Editas Medicine (EDIT) FCF Margin (2015 - 2025)
Editas Medicine (EDIT) reported FCF Margin of 407.38% for Q3 2025, up 9059098.0% year-over-year from N/an in Q3 2024, and up 70.97% on a QoQ basis from 1403.35% in Q2 2025.
Editas Medicine (EDIT) has 11 years of FCF Margin data on file, last reported at 407.38% in Q3 2025.
- Quarterly FCF Margin rose 9059098.0% year-over-year to 407.38% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 369.52% (down 6595.0% YoY) and the FY2024 annual result came in at 650.95%, down 48068.0% from the prior year.
- FCF Margin rose to 407.38% in Q3 2025 per EDIT's latest filing, from 1403.35% in the prior quarter.
- Across five years, FCF Margin topped out at 32.76% in Q4 2023 and bottomed at 122311.9% in Q3 2022.
- The 5-year median for FCF Margin is 760.23% (2022), against an average of 13120.33%.
- The widest annual swing landed in 2022, when FCF Margin tumbled 12166154 bps; it then jumped 12158741 bps in 2023.
- Tracing EDIT's FCF Margin over 5 years: stood at 278.56% in 2021, then plunged by 136 bps to 656.32% in 2022, then jumped by 95 bps to 32.76% in 2023, then sank by 324 bps to 139.0% in 2024, then tumbled by 193 bps to 407.38% in 2025.
- Per Business Quant, the three latest EDIT FCF Margin figures stand at 407.38% (Q3 2025), 1403.35% (Q2 2025), and 1028.62% (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -407.38% |
| Jun 30, 2025 | -1,403.35% |
| Mar 31, 2025 | -1,028.62% |
| Dec 31, 2024 | -139.00% |
| Sep 30, 2024 | -90,998.36% |
| Jun 30, 2024 | -11,804.29% |
| Mar 31, 2024 | -4,558.85% |
| Dec 31, 2023 | -32.76% |
| Sep 30, 2023 | -724.49% |
| Jun 30, 2023 | -1,284.48% |
| Mar 31, 2023 | -381.77% |
| Dec 31, 2022 | -656.32% |
| Sep 30, 2022 | -122,311.90% |
| Jun 30, 2022 | -561.52% |
| Mar 31, 2022 | -760.23% |
| Dec 31, 2021 | -278.56% |
| Sep 30, 2021 | -650.36% |
| Jun 30, 2021 | -10,541.42% |
| Mar 31, 2021 | -762.63% |
| Dec 31, 2020 | -348.94% |
| Sep 30, 2020 | -82.30% |
| Jun 30, 2020 | -304.19% |
| Mar 31, 2020 | -982.67% |
| Dec 31, 2019 | 364.47% |
| Sep 30, 2019 | -812.47% |
| Jun 30, 2019 | -1,096.39% |
| Mar 31, 2019 | -1,418.99% |
| Dec 31, 2018 | 65.48% |
| Sep 30, 2018 | -74.45% |
| Jun 30, 2018 | -230.26% |
| Mar 31, 2018 | -575.22% |
| Sep 30, 2017 | 220.98% |
| Jun 30, 2017 | 1,375.88% |
| Mar 31, 2017 | 10,137.10% |
| Dec 31, 2016 | -1,884.86% |
| Sep 30, 2016 | -1,578.07% |
| Jun 30, 2016 | -338.75% |
| Mar 31, 2016 | -1,261.49% |
| Dec 31, 2015 | -1,061.74% |
| Sep 30, 2015 | -1,810.45% |
| Jun 30, 2015 | 11,808.98% |